Two newer classes of drugs to treat adult-onset diabetes may be no more effective than the old standby, yet they cost significantly more over the course of a patient's disease.

That's according to a National Science Foundation-funded study by researchers at the University of Michigan, Mayo Clinic and North Carolina State University.